VERASTEM ONCOLOGY DOSES FIRST PATIENT IN TARGET-D 202 PHASE 2 REGISTRATION-DIRECTED TRIAL OF VS-7375 FOR KRAS G12D-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

Reuters · 1d ago

Please log in to view news